📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 15:09
477 analysed today
FollowTelegram
477
Today
149,878
All-time analysed
42,959
Positive
6,669
Negative
91,543
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
14 announcements match the current filters (relevance ≥ 5).
105% YoY growth in Consolidated Net Profit to ₹2.05 Cr in Q1 FY27
Lyka Labs reported a strong turnaround in Q1 FY27, with consolidated net profit rising 105.44% YoY to ₹2.05 Cr. Revenue from operations grew 28.11% YoY to ₹42.31 Cr, representing approximately 34% of the company's TTM revenue in a single quarter. Growth was primarily driven by a 68% surge in export revenue and a 62% increase in domestic branded formulations. However, consolidated EBITDA margins compressed to 11.74% from 13.07% in the previous year, indicating higher operating costs despite the volume growth.
Confidence: HIGH
What changedLyka Labs issued a revised press release for its Q1 FY27 results to correct typographical errors in specific financial figures from the original August 10 filing.
Why it mattersThe results indicate a significant operational recovery for a company that had a TTM net loss of ₹10 Cr, with quarterly revenue now tracking at a much higher run rate than the previous fiscal year.
Consolidated Net Profit (Q1): ₹2.05 CrRevenue from Operations (Q1): ₹42.31 CrQ1 Revenue vs TTM Revenue: ~33.8%Export Revenue Growth: 68.03%Consolidated EBITDA Margin: 11.74%
📅 Short termThe sharp turnaround in profitability and strong export performance are likely to be viewed positively by the market in the coming weeks.
📈 Long termIf the company maintains this quarterly revenue run rate of ~₹42 Cr, it could significantly exceed its TTM revenue of ₹125 Cr, potentially leading to a structural re-rating if profitability remains consistent.
⚠ Risk flags
- EBITDA margin compression of 133 basis points YoY
- 13.64% decline in P2P (Peer-to-Peer) domestic sales
- Historical volatility in earnings with a TTM net loss of ₹10 Cr
Key Highlights
Consolidated Net Profit increased by 105.44% YoY to ₹204.66 Lacs (₹2.05 Cr).
Export Revenue grew by 68.03% YoY to ₹1,483.42 Lacs (₹14.83 Cr).
Consolidated Revenue from Operations reached ₹4,230.94 Lacs, up 28.11% YoY.
Domestic Branded Formulation sales surged 62.27% to ₹737.67 Lacs.
Consolidated EBITDA margin contracted to 11.74% compared to 13.07% in Q1 FY26.
👀 What to Watch
Investors should monitor if the strong export growth momentum can be sustained in subsequent quarters and watch for stabilization in EBITDA margins, which declined despite the revenue jump.
105% YoY Profit Growth in Q1 FY27; Consolidated Revenue up 27% to Rs 42.73 Cr
Lyka Labs reported a strong turnaround in Q1 FY27, with consolidated net profit rising 105.44% YoY to Rs 2.05 Cr. Total consolidated income grew 26.95% YoY to Rs 42.73 Cr, driven by a significant 68% surge in export revenue and a 98% jump in branded veterinary sales. However, consolidated EBITDA margins saw compression, falling to 11.74% from 13.07% in the year-ago period. The quarterly revenue of Rs 42.31 Cr represents approximately 34% of the company's TTM revenue of Rs 125 Cr, indicating a robust start to the fiscal year.
Confidence: HIGH
What changedLyka Labs has transitioned from a loss-making TTM position (-Rs 10 Cr PAT) to a profitable quarter, supported by strong growth in international markets and branded segments.
Why it mattersThe results suggest that recent capacity expansions (Rs 30 Cr increase in PPE) are beginning to generate higher-value sales, although margin pressure remains a concern.
Consolidated Net Profit: Rs 2.05 CrExport Revenue Growth: 68.03%Q1 Revenue vs TTM Revenue: ~33.8%Consolidated EBITDA Margin: 11.74%Domestic Branded Formulation Growth: 62.27%
📅 Short termThe sharp increase in net profit and strong export performance are likely to be viewed positively by the market in the coming weeks.
📈 Long termLong-term sustainability depends on the company's ability to manage its high trade receivables and maintain the growth momentum in branded formulations.
⚠ Risk flags
- EBITDA margin compression
- Decline in P2P segment revenue (-13.64%)
- Historical risk of international trade receivable defaults
Key Highlights
Consolidated Net Profit increased by 105.44% YoY to Rs 2.05 Cr
Export Revenue surged 68.03% YoY to Rs 14.83 Cr
Branded Veterinary segment grew 97.83% YoY to Rs 5.87 Cr
Consolidated EBITDA margin compressed by 133 bps to 11.74%
Domestic Branded Formulation sales grew 62.27% YoY to Rs 7.38 Cr
👀 What to Watch
Investors should monitor if the high growth in exports and branded formulations can be sustained to offset the 13.6% decline in the P2P segment and stabilize operating margins.
Lyka Labs reports ₹10.44 Cr Q1 loss; Board approves 100% divestment of Lyka BDR subsidiary
Lyka Labs reported a weak Q1 FY27 with consolidated revenue declining 20.8% YoY to ₹32.30 Cr. The company swung to a consolidated net loss of ₹10.44 Cr, compared to a profit of ₹0.99 Cr in the same period last year. Concurrently, the board approved the 100% divestment of its subsidiary, Lyka BDR International Limited, which contributed 8% to FY26 revenue but carries a negative net worth of ₹4.49 Cr. Standalone results were further weighed down by a significant exceptional loss of ₹23.01 Cr, likely related to subsidiary adjustments.
Confidence: HIGH
What changedThe company has transitioned from a marginal profit to a significant loss and has formally decided to exit its international subsidiary, Lyka BDR International.
Why it mattersThe divestment of a negative net worth subsidiary may clean up the balance sheet in the long run, but the immediate sharp drop in revenue and high finance costs indicate ongoing operational and liquidity stress.
Consolidated Revenue (Q1 FY27): ₹32.30 CrConsolidated Net Loss (Q1 FY27): ₹10.44 CrSubsidiary Revenue Contribution (FY26): 8%Subsidiary Net Worth: ₹-4.49 CrExceptional Loss (Standalone): ₹23.01 Cr
📅 Short termNegative sentiment is likely due to the widening losses and revenue contraction. The market will wait for details on the divestment valuation.
📈 Long termThe exit from a loss-making/negative net worth subsidiary could be structurally positive if it allows the company to focus on its core formulations business, though current debt levels remain a concern.
⚠ Risk flags
- Widening net losses
- Significant revenue contraction (20.8% YoY)
- High finance costs relative to revenue
- Negative net worth of the subsidiary being divested
Key Highlights
Consolidated revenue for Q1 FY27 fell to ₹32.30 Cr from ₹40.78 Cr in Q1 FY26.
Net loss for the quarter stood at ₹10.44 Cr against a profit of ₹0.99 Cr in the year-ago period.
Board approved 100% divestment of Lyka BDR International Limited, which had a negative net worth of ₹4.49 Cr as of March 2026.
Standalone results included a large exceptional loss of ₹23.01 Cr, impacting the standalone bottom line significantly.
Finance costs remained elevated at ₹4.53 Cr for the quarter, representing 14% of consolidated revenue.
👀 What to Watch
Investors should monitor the final sale consideration for Lyka BDR International and whether the exit improves consolidated margins. Watch for management commentary on the ₹23.01 Cr standalone exceptional item and the strategy to arrest the 20% revenue decline.
Lyka Labs Promoters Acquire 55,967 Equity Shares via Open Market Purchases
Promoters and members of the promoter group of Lyka Labs Limited have collectively acquired 55,967 equity shares through open market transactions between June 24 and June 25, 2026. The acquisitions were made by Kunal N. Gandhi, Nehal N. Gandhi, Alisha K. Gandhi, and Enai Trading and Investment Private Limited. Nehal Gandhi made the largest individual purchase of 33,122 shares. Such insider buying is typically viewed as a sign of management's confidence in the company's valuation and future prospects.
Key Highlights
Total of 55,967 equity shares acquired by the promoter group via open market transactions
Nehal N. Gandhi acquired 33,122 shares on June 24 and 25, 2026
Enai Trading and Investment Private Limited purchased 11,312 shares on June 24, 2026
Kunal N. Gandhi and Alisha K. Gandhi acquired 6,533 and 5,000 shares respectively
Disclosures made under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations
👀 What to Watch
Investors should take note of this promoter buying as a positive sentiment indicator. It suggests that the insiders believe the current market price represents good value or that they have a positive outlook on the company's growth.
Lyka Labs Allots 4.62 Lakh Equity Shares Following Merger with Lyka Exports
Lyka Labs Limited has approved the allotment of 4,62,711 equity shares to the shareholders of Lyka Exports Limited as part of a court-sanctioned Scheme of Amalgamation. The allotment follows a swap ratio of 23 shares of Lyka Labs for every 100 shares held in Lyka Exports. As a result, the company's total paid-up equity share capital has increased to Rs. 36.15 crore, comprising 3,61,52,711 shares. These new shares will rank pari-passu with existing shares and are set to be listed on both BSE and NSE.
Key Highlights
Approved allotment of 4,62,711 equity shares of face value Rs. 10 each.
Share exchange ratio fixed at 23:100 (23 Lyka Labs shares for every 100 Lyka Exports shares).
Paid-up equity capital increased to Rs. 36,15,27,110 from the previous level.
The record date for determining eligible shareholders was June 04, 2026.
New shares will be listed on BSE and NSE and rank equally with existing equity.
👀 What to Watch
Investors should note the completion of the merger process and the subsequent minor equity dilution; no immediate action is required as this is a procedural update.
Lyka Labs to Impair Rs 23.01 Cr in Subsidiary; Sets June 4 as Record Date for Merger
Lyka Labs has announced a significant impairment loss of Rs. 2301.44 Lakhs (Rs. 23.01 Cr) regarding its subsidiary, Lyka BDR International, due to continuous operational losses and eroded net worth. Simultaneously, the company has fixed June 4, 2026, as the record date for its merger with Lyka Exports Limited. Under the sanctioned scheme, shareholders of Lyka Exports will receive 23 shares of Lyka Labs for every 100 shares held. The company's FY26 financial results have been restated to reflect the merger impact from April 1, 2024.
Key Highlights
Recognized impairment loss of Rs. 2301.44 Lakhs for subsidiary Lyka BDR International, covering both equity and loans.
Fixed June 04, 2026, as the Record Date for the merger with Lyka Exports Limited.
Share swap ratio set at 23 equity shares of Lyka Labs for every 100 shares of Lyka Exports.
Statutory auditors issued an unmodified opinion on FY26 results, though figures were restated for the merger.
The 47th Annual General Meeting is scheduled for August 10, 2026.
👀 What to Watch
Investors should evaluate the impact of the Rs. 23 crore write-off on the company's net worth while monitoring the completion of the Lyka Exports merger for potential synergies. Shareholders of Lyka Exports must ensure holdings are in place by June 4 to qualify for the share swap.
Lyka Labs Credit Rating Affirmed at IND BBB+/Stable for Reduced INR 332.8M Facility
India Ratings & Research has affirmed Lyka Labs Limited's credit rating for its bank loan facilities. The total facility size has been reduced to INR 332.8 million from the previous INR 363.1 million. The long-term rating is maintained at IND BBB+ with a Stable outlook, while the short-term rating stands at IND A2. This affirmation indicates that the company's credit profile remains stable despite the slight reduction in the bank loan facility size.
Key Highlights
India Ratings affirmed the rating for bank facilities totaling INR 332.8 million.
The facility size was reduced from the previous amount of INR 363.1 million.
Long-term rating maintained at IND BBB+ with a Stable outlook.
Short-term rating affirmed at IND A2.
👀 What to Watch
The affirmation of the credit rating suggests financial stability; investors should continue to monitor the company's debt management and operational performance.
Lyka Labs Completes Merger with Lyka Exports; Authorized Capital Rises to ₹59 Crore
Lyka Labs Limited has successfully completed the amalgamation of Lyka Exports Limited into itself, effective from April 8, 2026. The merger follows the sanction from the NCLT Ahmedabad Bench and the subsequent filing with the Registrar of Companies. The appointed date for this scheme is retrospectively set to April 1, 2022. Consequently, the company's authorized share capital has been increased to ₹59 crore to accommodate the merger requirements.
Key Highlights
Scheme of Amalgamation with Lyka Exports Limited became effective on April 8, 2026
The retrospective appointed date for the merger is April 1, 2022
Authorized share capital increased to ₹59,00,00,000 (₹59 Crores)
New capital structure consists of 5.7 crore equity shares of ₹10 each and 2 lakh preference shares
Consolidation aims to streamline operations and integrate the export business directly
👀 What to Watch
Investors should view this consolidation as a positive step toward corporate simplification and operational synergy. Monitor upcoming financial statements for the impact of the integrated export business on the bottom line.
NCLT Approves Merger of Lyka Exports Limited with Lyka Labs Limited
The National Company Law Tribunal (NCLT), Ahmedabad Bench, has officially approved the Scheme of Amalgamation between Lyka Exports Limited and Lyka Labs Limited. The order was granted on March 16, 2026, following a petition filed in 2024. Notably, the merger has a retrospective appointed date of April 1, 2022, which will lead to a consolidation of financial statements from that period. The company is now completing the final regulatory step of filing e-form INC-28 with the Registrar of Companies within the 30-day deadline.
Key Highlights
NCLT Ahmedabad Bench approved the merger on March 16, 2026
The appointed date for the amalgamation is retrospectively set as April 1, 2022
Lyka Exports Limited (Transferor) will be fully merged into Lyka Labs Limited (Transferee)
Company to file e-form INC-28 with the Registrar of Companies within 30 days to finalize the process
👀 What to Watch
Investors should view this as a positive consolidation move that may improve operational efficiencies; however, they should review the upcoming consolidated financial statements to understand the impact of the 2022 retrospective appointed date.
Lyka Labs Amalgamation Update: NCLT Reserves Order Following FEMA Compliance Review
Lyka Labs Limited has provided a regulatory update regarding its ongoing Scheme of Amalgamation. The National Company Law Tribunal (NCLT) has reviewed the company's submissions and affidavits concerning FEMA compliance and Import Export Code guidelines. Following these submissions, the NCLT has officially reserved its order on the matter. This indicates that the judicial hearing phase is complete, and a final decision on the merger is expected shortly.
Key Highlights
NCLT has reserved the final order regarding the Scheme of Amalgamation for Lyka Labs.
Company submitted compliance affidavits related to FEMA guidelines and Import Export Code as directed.
The update follows a previous regulatory intimation dated February 2, 2026.
The tribunal's jurisdiction covers both the Transferor and Transferee companies involved in the deal.
👀 What to Watch
Investors should await the final NCLT order as it will determine the legal completion of the merger. Monitor the stock for price sensitivity once the final judgment is made public.
Lyka Labs Amalgamation Update: NCLT Hearing Scheduled for February 19, 2026
Lyka Labs Limited has provided a procedural update regarding its ongoing Scheme of Amalgamation before the NCLT Ahmedabad Bench. During the hearing on January 29, 2026, the company confirmed it has complied with all previous tribunal orders. The NCLT is currently examining an affidavit filed by the company specifically regarding FEMA compliance. The matter has now been listed for a subsequent hearing on February 19, 2026.
Key Highlights
NCLT Ahmedabad Bench reviewed the amalgamation application on January 29, 2026
Company confirmed compliance with all previous orders passed by the Hon’ble Tribunal
Tribunal is currently examining a specific affidavit regarding FEMA compliance
Next hearing for the amalgamation scheme is scheduled for February 19, 2026
👀 What to Watch
Investors should track the outcome of the February 19 hearing as the amalgamation is a significant corporate restructuring event. Maintain a watch on the stock for any volatility leading up to the final NCLT approval.
Lyka Labs Q3 Results: Standalone Profit Jumps to ₹2.7 Cr; Consolidated Swings to Loss
Lyka Labs reported a mixed performance for the quarter ended December 31, 2025. On a standalone basis, the company saw a significant jump in net profit to ₹269.85 lakhs from ₹26.14 lakhs in the previous year. However, the consolidated results show a net loss of ₹15.12 lakhs compared to a profit of ₹270.40 lakhs in Q3 FY25, driven by a 9% decline in consolidated revenue. The company also accounted for a one-time impact of ₹11.41 lakhs related to new Labour Code regulations.
Key Highlights
Standalone Net Profit surged to ₹269.85 lakhs from ₹26.14 lakhs YoY.
Consolidated Revenue from operations fell to ₹3,072.80 lakhs from ₹3,379.76 lakhs YoY.
Consolidated bottom line swung to a loss of ₹15.12 lakhs from a profit of ₹270.40 lakhs in the year-ago period.
Company paid a premium of ₹217.14 lakhs on the redemption of 1,08,570 preference shares, adjusted against General Reserve.
Recognized a one-time incremental impact of ₹11.41 lakhs under Employee Benefit Expenses due to new Labour Codes.
👀 What to Watch
Investors should exercise caution as the consolidated performance indicates significant weakness in subsidiaries, leading to an overall group loss despite standalone growth. Monitor the company's ability to stabilize consolidated margins in the upcoming quarters.
Lyka Labs Amalgamation Order Delayed; NCLT Sets Next Hearing for January 29, 2026
Lyka Labs has provided an update regarding its Scheme of Amalgamation currently under review by the NCLT Ahmedabad Bench. While the order was previously reserved on December 5, 2025, the tribunal called for further clarifications on December 18, 2025. Consequently, the matter has now been scheduled for further consideration on January 29, 2026. This delay extends the timeline for the completion of the merger process for both the Transferor and Transferee companies.
Key Highlights
NCLT Ahmedabad Bench had previously reserved the order on December 5, 2025.
The matter was listed for further clarification on December 18, 2025.
The next hearing for further consideration is scheduled for January 29, 2026.
The amalgamation involves both the Transferor and Transferee companies under the same jurisdiction.
👀 What to Watch
Investors should monitor the outcome of the January 29 hearing as it will determine the progress of the merger. The delay may cause short-term price volatility due to extended uncertainty.
LYKALABS: NCLT reserves order on Scheme of Amalgamation
Lyka Labs Limited announced that the Hon’ble National Company Law Tribunal (NCLT), Ahmedabad Bench, has reserved its order regarding the Scheme of Amalgamation. This follows an earlier update on November 8th, 2025, and a last opportunity granted to the Income Tax counsel to file a reply. The Income Tax Department's counsel has stated no objection to the merger application. The company received a copy of the NCLT order on December 5th, 2025.
Key Highlights
NCLT Ahmedabad Bench reserved its order on the Scheme of Amalgamation.
Income Tax Department's counsel has no objection to the merger application.
Company received NCLT order copy on December 5th, 2025.
👀 What to Watch
Investors should monitor further announcements from the company regarding the NCLT order. Review the company's website for more information on the amalgamation scheme.
